drugset / Trial / NCT00822978

Phase 1 Study for Safety of ACHN-490

NCT00822978

Phase 1 Completed 39 enrolled Achaogen, Inc.
RandomizedParallel-groupQuadruple-blind

Summary

This is a first-in-human phase 1 study to assess if ACHN-490 Injection is safe in people. Groups of people will receive either the study medication (ACHN-490) or a placebo (normal saline) as a single infusion. If the single dose is well tolerated then this group will receive 1 dose per day for up to 10 consecutive days. A new group of people will receive the study medication at a higher dose than the previous dose level as long as the previous dose was safe.

Timeline

Start
2009-01
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator plazomicin Small molecule 4 mg/kg Intravenous
Comparator plazomicin Small molecule 15 mg/kg Intravenous

Indications

No indication recorded.